Inhaled therapies in patients with moderate COPD in clinical practice: Current thinking

Amnon Ariel, Alan Altraja, Andrey Belevskiy, Piotr W. Boros, Edvardas Danila, Matjaz Fležar, Vladimir Koblizek, Zvi G. Fridlender, Kosta Kostov, Alvils Krams, Branislava Milenkovic, Attila Somfay, Ruzena Tkacova, Neven Tudoric, Ruxandra Ulmeanu, Arschang Valipour*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.

Original languageAmerican English
Pages (from-to)45-56
Number of pages12
JournalInternational Journal of COPD
Volume13
DOIs
StatePublished - 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Ariel et al.

Keywords

  • Anticholinergic
  • Dual bronchodilation
  • Inhaled corticosteroid
  • LABA
  • LAMA
  • Tiotropium

Fingerprint

Dive into the research topics of 'Inhaled therapies in patients with moderate COPD in clinical practice: Current thinking'. Together they form a unique fingerprint.

Cite this